23andMe, Inc. (the "Company") is excited to support the Avon Longitudinal Study of Parents and Children ("ALSPAC") by providing the genotyping support described in this letter agreement. With the goal of genotyping 11,000 children already enrolled in the ALSPAC study, the Company will provide Illumina Human550+ Quad DNA Analysis BeadChips (each of which can process four samples and analyses approximately 610,000 loci and each of which contain the custom content generated and designed by 23andMe) (the "BeadChips") to process a maximum of 11,000 samples, plus another 1,000 for failures in processing.

The Company will ship that number of BeadChips to process approximately 1,000 samples to the Wellcome Trust Sanger Institute laboratory ("Sanger") and the remainder of the BeadChips to the National Genetics Institute laboratory ("NGI") (collectively the "Laboratories"), at which Laboratories the samples will be genotyped. Sanger's processing fees per sample shall be as set forth on Exhibit A, which cost shall not exceed the actual cost of processing by Sanger as represented by the Sanger. The Company will pay these processing costs as the genotyping occurs and is confirmed to the Company on written invoice. The Company will also pay the processing costs for samples processed by NGI pursuant to the terms of a separate agreement. The University of Bristol represents that only samples of children already enrolled in the ALSPAC study will be shipped to the Laboratories to be genotyped with the BeadChips and that the 11,000 number of samples processed shall only be exceeded to re-process samples that fail processing up to the maximum of 12,000. The Company is aware that genotyping data produced by the Laboratories of the ALSPAC participants under this letter agreement shall be the property of University of Bristol and reintegrated into the ALSPAC dataset.

As consideration for the support described above, each of Bristol University and Sanger, to the extent applicable, agrees that: 1) it shall not utilize the BeadChips except for the purposes set forth in this letter agreement, 2) it shall not utilize any information provided by 23andMe, Inc. to process the BeadChips, including but not limited to decoding files or other services provided to aid in the decoding of the DNA samples using the BeadChips, other than in order to process the BeadChips for the purposes set forth in this letter agreement (the BeadChips and information provided therewith the "Proprietary Information"), 3) shall maintain as confidential the Proprietary Information, applying the same measures to protect such Proprietary Information as it does its own confidential information, and 4) that 23andMe shall be permitted to discuss and announce that it is funding the genotyping of the ALSPAC children and that it may send a Research Fellow to analyze the ALSPAC dataset.

The Company agrees that the Laboratories shall provide the resulting data from the genotyping directly to the University of Bristol and that the Company shall not receive such data from either laboratory. However, if either laboratory requests aid from the Company in processing the data under this letter agreement, the Company shall be happy to provide reasonable assistance.

The University of Bristol agrees that a Research Fellow can be attached to the MRC Centre for Causal Analyses and Translational Epidemiology at the Department of Social Medicine, University of Bristol, where they will be able to analyze the data in the same manner as the other analysts, for a period of up to six (6) months subject to the terms of a secondment agreement to be agreed between University of Bristol and 23andMe.